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ABSTRACT:
Acute myeloid leukemia (AML) is a life-threatening stem cell disease 
characterized by uncontrolled proliferation and accumulation of myeloblasts. Using an 
advanced RNAi screen-approach in an AML mouse model we have recently identified 
the epigenetic ‘reader’ BRD4 as a promising target in AML. In the current study, we 
asked whether inhibition of BRD4 by a small-molecule inhibitor, JQ1, leads to growth-
inhibition and apoptosis in primary human AML stem- and progenitor cells. Primary 
cell samples were obtained from 37 patients with freshly diagnosed AML (n=23) or 
refractory AML (n=14). BRD4 was found to be expressed at the mRNA and protein 
level in unfractionated AML cells as well as in highly enriched CD34+/CD38- and 
CD34+/CD38+ stem- and progenitor cells in all patients examined. In unfractionated 
leukemic cells, submicromolar concentrations of JQ1 induced major growth-inhibitory 
effects (IC50 0.05-0.5 µM) in most samples, including cells derived from relapsed or 
refractory patients. In addition, JQ1 was found to induce apoptosis in CD34+/CD38− 
and CD34+/CD38+ stem- and progenitor cells in all donors examined as evidenced 
by combined surface/Annexin-V staining. Moreover, we were able to show that JQ1 
synergizes with ARA-C in inducing growth inhibition in AML cells. Together, the BRD4-
targeting drug JQ1 exerts major anti-leukemic effects in a broad range of human 
AML subtypes, including relapsed and refractory patients and all relevant stem- and 
progenitor cell compartments, including CD34+/CD38− and CD34+/CD38+ AML cells. 
These results characterize BRD4-inhibition as a promising new therapeutic approach 
in AML which should be further investigated in clinical trials.
INTRODUCTION
Acute myeloid leukemia (AML) is a stem cell-
derived hematopoietic malignancy characterized 
by uncontrolled proliferation and accumulation of 
myeloblasts in the bone marrow (BM), blood, and other 
organs. The clinical course and prognosis in AML vary, 
depending on age, the biology and category of the disease, 
cytogenetic features and number and types of deregulated 
genes [1-6]. In a subset of patients, cytogenetic and/Oncotarget 2012; 3: 1588-1599 1589 www.impactjournals.com/oncotarget
or molecular features are indicative of a more favorable 
prognosis. When treated with repeated chemotherapy 
cycles or/and hematopoietic stem cell transplantation 
(SCT), these patients have a relatively good prognosis and 
many of them enter long-term disease-free survival [1-8]. 
However, not all patients with AML have a suitable donor 
or are eligible for SCT. In other patients, the response to 
chemotherapy is poor or short-lived. For AML patients 
who relapse or have resistant disease, therapeutic options 
are limited. Current research is seeking novel drug targets 
and novel, more potent, drugs for these poor-risk patients 
[9-13].
One key event in oncogenic transformation in 
AML is the corruption of myeloid cell-fate programs 
resulting in the generation of aberrantly self-renewing 
cells, the so-called leukemic stem cells (LSC), which 
maintain and propagate the disease and are often resistant 
to conventional chemotherapy [14-16]. Notably, in 
AML and other myeloid leukemias, the malignant clone 
is organized hierarchically with more mature cells 
programmed to undergo apoptosis after a variable number 
of cell divisions, and immature primitive cells that have 
self-renewing and leukemia-propagating capacity [14-18]. 
Although the exact phenotype of LSC in AML remains 
uncertain, several studies have suggested that in various 
AML subtypes, the NOD/SCID mouse-repopulating LSC 
reside within a CD34+/CD38− fraction of the leukemic 
clone [16-21]. Other studies have shown that NSG 
mouse-repopulating AML stem cells reside in both the 
CD34+/CD38+ and the CD34+/CD38− fraction of AML 
cells, or even in CD34− subfractions of the clone [22,23]. 
Clinically, the LSC concept is of great importance and 
may have prognostic and therapeutic implications [24-
32]. Notably, strategies aimed at terminating aberrant 
self-renewal or survival of LSC are considered key to the 
development of more effective therapies [26-32].
In an effort to systematically probe genes involved 
in chromatin regulation as potential therapeutic targets, 
we have recently developed an unbiased screen approach, 
combining AML mouse models and new in vivo RNAi 
technologies. Through this approach we were able to 
identify the epigenetic ‘reader’ Bromodomain-containing 
4 Protein (BRD4) as a new potential target in AML [33]. 
Inhibition of BRD4 using BRD4-specific RNAi or JQ1, a 
BET bromodomain inhibitor that blocks BRD4-binding to 
acetylated histones, showed profound antileukemic effects 
in AML mouse models as well as in various human AML 
cell lines and in primary leukemic cells obtained from 
AML patients [33].
In the present study, we extended these analyses to 
various subtypes of AML as well as to AML LSC. The 
specific aim of our study was to evaluate BRD4-inhibition 
as a potential therapeutic approach to target and eliminate 
LSC in AML. To address this question, we analyzed the 
effects of JQ1 on primary neoplastic stem- and progenitor 
cells obtained from patients with freshly diagnosed or 
refractory AML. In addition, we asked whether JQ1 would 
synergize with conventional cytostatic drugs to produce 
synergistic anti-leukemic effects in AML.
RESULTS
BRD4 is expressed in AML cells including CD34+ 
stem- and progenitor cells
As assessed by qPCR analysis, BRD4 mRNA was 
found to be expressed in highly enriched sorted CD34+/
CD38+ AML progenitor cells and CD34+/CD38− stem cells 
(Figure 1A). In addition, all AML cell lines examined 
(HL60, U937, KG1, MV4-11, MOLM-13) were found 
to express BRD4 mRNA (not shown). Expression of 
the BRD4 protein in AML cells was examined by ICC 
and IHC. As assessed by ICC, BRD4 was found to be 
expressed in primary AML cells (blasts) in all donors 
without negative subpopulations (Figure 1B). More 
importantly, we found that in all donors examined, the 
CD34+/CD38+ and the CD34+/CD38− stem- and progenitor 
cells express the BRD4 antigen without negative 
subpopulations (Figure 1B). No differences in BRD4 
expression were seen when comparing different FAB or 
WHO subtypes of AML. In addition, all AML cell lines 
tested were found to stain positive for BRD4 (Figure 1C). 
BRD4 was found to be expressed in both the cytoplasmic 
compartment and nuclear compartment of leukemic cells 
in all patients and all cell lines tested (Figure 1B and 1C), 
and the same was found when normal BM cells or cord 
blood cells were analyzed (not shown). Preincubation of 
the anti-BRD4 antibody with a specific blocking peptide 
resulted in a negative stain (Figure 1C). Corresponding 
results were obtained by IHC. Again, BRD4 was found to 
be expressed in the nuclear and cytoplasmic compartment 
of leukemic cells in all donors and all AML variants tested 
(Figure 1D). In the normal BM, BRD4 was also expressed 
in myeloid progenitor cells as well as in megakaryocytes. 
However, compared to the leukemic marrow, BRD4 
expression appeared to be more restricted to the nuclear 
compartment of myeloid cells. Table 1 shows the 
distribution of BRD4 in the various cellular compartments 
in AML and in control BM sections. Together, our data 
show that BRD4 is expressed in both the cytoplasm and in 
the nuclei of AML blasts and AML LSC.
The BRD4-targeting drug JQ1 inhibits 
proliferation of leukemic cells in freshly diagnosed 
and relapsed or refractory AML
Confirming  our  previous  data  [33]  the  BET 
bromodomain  inhibitor  JQ1  was  found  to  block 
3H-thymidine uptake and thus proliferation in Oncotarget 2012; 3: 1588-1599 1590 www.impactjournals.com/oncotarget
Figure 1: Expression of BRD4 in leukemic cells in acute myeloid leukemia (AML). A: Highly purified (sorted) CD34+/
CD38- and CD34+/CD38+ stem and progenitor cells of 9 patients with AML were subjected to RNA isolation and qPCR as described in the 
text. BRD4 mRNA levels are shown as percent of ABL mRNA levels. Results are expressed as mean±S.D. of 9 donors. B: Detection of the 
BRD4 protein in the cytoplasm and in the nuclei of CD34+/CD38- (left panels) and CD34+/CD38+ stem- and progenitor cells (middle panels) 
purified from mononuclear cells (MNC) by cell sorting (purity >98%) in 2 patients with AML (numbers refer to patients shown in Table 3). 
Immunocytochemistry was performed on cytospin slides using an anti-BRD4 antibody. The staining reaction in the total (non-sorted) MNC 
fraction is also shown (right panels). C: Expression of BRD4 in AML cell lines (HL60, KG-1, U937, MOLM13, MV4-11) as determined 
by indirect immunocytochemistry using an anti-BRD4 antibody. In the lower panel, the anti-BRD4 antibody was preincubated with control 
medium (-bP; lower left panel) or with a BRD4-specific blocking peptide (+bP, lower right panel) before being applied on U937 cells. D: 
Immunohistochemical detection of BRD4 in AML cells in bone marrow sections obtained from patients with AML (FAB categories M1, 
M2, M3, M4, and M5). Again, BRD4 was detected in the cytoplasm as well as in the nuclei of AML blasts. Indirect immunohistochemistry 
was performed using an anti-BRD4 antibody.Oncotarget 2012; 3: 1588-1599 1591 www.impactjournals.com/oncotarget
unfractionated primary AML blasts. In particular, JQ1 was 
found to inhibit the proliferation of leukemic cells in 27/28 
AML patients tested, with reasonable IC50 values (<1 µM) 
(Table 2). Anti-leukemic effects of JQ1 were seen in all 
patients with primary, untreated AML (n=18), and in 9/10 
patients (90%) with relapsed or refractory AML (Table 2). 
In the responding patients, IC50 values ranged between 20 
and 450 nM (median: 100 nM) without major differences 
when comparing freshly diagnosed AML patients with 
relapsed or refractory AML (Table 2, Figure 2A). In 
normal BM samples (n=3), JQ1 also produced growth 
inhibition, but the IC50 values were higher compared to 
that found in AML cells (IC50: 100-500 nM, median: 250 
nM).
JQ1 induces apoptosis in primary AML cells
In a next step, we examined the mechanism(s) of 
JQ1-induced growth inhibition in AML cells. In these 
experiments,  JQ1  was  found  to  induce  apoptosis  in 
primary AML cells in all samples tested, including cells 
derived from freshly diagnosed or relapsed patients. 
Induction of apoptosis was measured by light microscopy 
(Figure 3A) as well as by caspase 3 staining and flow 
cytometry (Figure 3B). JQ1 also produced apoptosis in all 
AML cell lines tested confirming our previous data (not 
shown) [33].
Figure 2: Effects of JQ1 on proliferation of AML cells. A: Isolated AML blasts of 22 patients with AML were incubated in 
control medium (Co) or medium containing various concentrations of JQ1, as indicated, at 37°C and 5% CO2 for 48 hours. Then, uptake of 
3H-thymidine was measured. Results are expressed as percent of medium control and show the mean±S.D. values from these 22 patients. 
B: AML blasts from patient #9 (in Table 3) were incubated in control medium or medium containing various concentrations of JQ1 (as 
indicated) at 37°C and 5% CO2 for 48 hours. Then, uptake of 3H-thymidine was measured. Results are expressed as percent of control and 
show the mean±S.D. of triplicates.
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Table 1: Cellular distribution of BRD4 in bone marrow (BM) sections in AML and controls
 cytoplasmic BRD4 staining  nuclear BRD4 staining
Cell type
normal/ 
reactive BM
primary 
AML
relapsed/
refractory 
AML
normal/ 
reactive BM
primary 
AML
relapsed/
refractory 
AML
Megakaryocytes +/- +/- + + + +
Myeloblasts n.d. +/- + n.d. +/- +
Myeloid 
progenitor cells
+/- + + + + +
Neutrophil 
granulocytes
+/- +/- +/- +/- +/- +/-
Eosinophil 
granulocytes
- +/- +/- +/- +/- +/-
Erythroid cells - - - - - -
Lymphocytes n.d. +/- +/- +/- +/- +/-
Bone marrow sections were stained with an anti-BRD4 antibody as described in the text.
Score: -, negative; +/-, weakly positive or positive in a smaller subset of cells; +, mostly positive.
Abbreviations: BM, bone marrow; AML, acute myeloid leukemia; n.d., not determined.Oncotarget 2012; 3: 1588-1599 1592 www.impactjournals.com/oncotarget
Table2: Effects of JQ1 on proliferation of primary leukemic cells 
3H-thymidine-uptake
AML No# FAB WHO  Source PB/BM
+cytokines** 
 IC50 (nM)   
-cytokines
IC50 (nM)
1* M1 AML with t(9;11) PB 280 n.t.
2 M5 AML monoblastic  BM 90 70
3 M5 AML with (9;11)/NPM1m BM 160 240
4 M4 AML with mutated NPM1 PB 1,030 420
5 M1 AML with mutated NPM1 BM 420 n.t.
6 M4 AML myelomonocytic BM 1,420 140
7 M1 AML with myelodysplasia BM 40 n.t.
8* M5 AML with myelodysplasia PB 40 40
9 M5 AML monoblastic BM 50 50
10 M4 AML with inv16 BM 150 70
11 M2 AML with t(8;21) BM 40 n.t.
12 M2 AML with t(8;21) BM 60 n.t.
13 RAEB-T AML with myelodysplasia BM n.t. 60
14 M1 AML without maturation BM n.t. 150
15* sec. AML with myelodysplasia PB n.t. 1,800
16* M6a acute erythroid leukemia PB 40 n.t.
17* M4 AML myelomonocytic BM n.t. 280
19 M4 Therapy related AML BM n.t. 250
20 M1 AML with mutated NPM1 BM n.t. 440
22* sec. AML with myelodysplasia BM n.t. 70
23* sec. AML with myelodysplasia PB n.t. 85
24* M4 AML myelomonocytic BM n.t. 230
25* sec. AML with myelodysplasia BM n.t. 90
26 M4 AML with myelodysplasia BM n.t. 260
27* M4 AML monocytic BM n.t. 20
28 M1 AML with mutated NPM1 BM n.t. 80
29 sec. AML with myelodysplasia BM n.t. 30
30 M5 AML with mutated NPM1 BM n.t. 110
*These patients were analyzed at relapse or persistence of blasts. **Cells were cultured in stem cell 
factor (SCF), interleukin-3 (IL-3) and granulocyte colony-stimulating factor (G-CSF) (each 100 ng/ml). 
Abbreviations: AML, acute myeloid leukemia; FAB, French-American-British cooperative study group; PB, 
peripheral blood; BM, bone marrow; n.t., not tested.Oncotarget 2012; 3: 1588-1599 1593 www.impactjournals.com/oncotarget
JQ1 induces apoptosis in CD34+/CD38+ and 
CD34+/CD38− leukemic stem- and progenitor cells 
in freshly diagnosed AML and relapsed/refractory 
AML
In a next step, we examined the effects of JQ1 on 
survival of leukemic stem- and progenitor cells derived 
from our AML patients. As shown in Figure 3C, JQ1 
induced apoptosis in CD34+/CD38+ as well as CD34+/
CD38− stem and progenitor cells in all samples and 
all donors tested, including patients with relapsed or 
refractory AML, and without major differences when 
comparing FAB or WHO subtypes.
JQ1 synergizes with ARA-C in producing growth 
inhibition in AML cells
Since JQ1 and other (similar) BET bromodomain 
inhibitors are considered to be used in clinical trials in 
AML patients in combination with conventional cytostatic 
drugs like ARA-C, we asked whether JQ1 and ARA-C 
would produce cooperative or even synergistic growth-
inhibitory effects on AML cells. For these experiments, the 
AML cell lines HL60 and KG1 were employed. As visible 
in Figure 4, JQ1 was found to exert strong synergistic 
antileukemic effects when combined with ARA-C in 
both cell lines (Figure 4). These data suggest that drug 
combinations employing conventional cytostatic drugs, 
like ARA-C and a BET bromodomain inhibitor, may 
produce synergistic antileukemic effects in AML cells.
DISCUSSION
Based on their self-renewal and disease-propagating 
capacity, leukemic stem- and progenitor cells represent 
an attractive therapeutic target in AML [26-32]. Notably, 
AML LSC are considered a relevant source of relapsing 
disease and exhibit intrinsic as well as acquired resistance 
[28-32]. Therefore, considerable efforts have been made 
to understand the mechanisms of LSC resistance, and to 
identify new drug targets that play an important role in 
survival, self renewal, and proliferation of AML LSC. 
However, so far, little is known about the expression 
of molecular targets in AML LSC and about effects of 
various targeted drugs [25-28]. We have recently shown 
that the epigenetic reader BRD4 is a novel promising 
target in AML [33]. In the present study, we have extended 
these analyses and show that AML LSC express BRD4, 
and that the BRD4-targeting drug JQ1 induces growth 
inhibition and apoptosis in these cells, which may have 
Figure 3: Effects of JQ1 on survival of AML stem- and progenitor cells. Primary AML cells were incubated in the absence 
(Co) or presence of JQ-1 (10–2,500 nM) for 48 hours. Then, the percentage of apoptotic cells was determined on Wright-Giemsa-stained 
cytospin preparations (A), and the percentage of active Caspase-3-positive cells was determined by flow cytometry (B). Results represent 
the mean±S.D. from 6 patients (A) or 3 patients (B). Asterisk: p<0.05 compared to medium control. C: Upper panel: Primary AML cells 
(n=9) were cultured in control medium (Co) or JQ1 (10-2,500 nM) at 37°C for 48 hours. CD34+/CD38+ AML progenitor cells and CD34+/
CD38− AML stem cells were examined by combined staining for surface antigens and Annexin-V-FITC. Apoptosis was expressed as 
percent Annexin-V-positive cells. Results in the upper panel represent the mean±S.D. from 9 donors. The lower panel shows an example 
of Annexin-V expression in CD34+/CD38− AML stem cells after exposure to control medium or JQ1 (1 µM) for 48 hours in patient #10. 
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Table 3: Patients´ Characteristics
Diagnosis %BlastCells
No# F/M
Age
Yrs
FAB WHO 
WBC
x109/L
PB BM Karyotype
Molecular Defects 
(Mutations)
1* F 32 M1 AML with t(9;11) 0.4 80% 73% 46,XX, t(9;11) MLL1-AF9
2 M 61 M5 AML monoblastic  35.1 33% 72% 46,XY, t(11;17) MLL1-MSF
3 M 65 M5 AML with t(9;11)/NPM1m 94.8 6% 90% 47,XY, t(9;11),+8 MLL1-AF9, 
FLT3m, NPM1m 
4∆ M 80 M4 AML with mutated NPM1 198.5 25% 52% 46,XY FLT3m, 
KIT D816V, NPM1m
5 M 54 M1 AML with NPM1m 361.5 95% 92% 46,XY FLT3m, NPM1m
6 F 49 M4 AML myelomonocytic 15.4 16% 63% 46,XX FLT3m, 
NPM1m, CEBPAm
7 M 67 M1 AML with myelodysplasia 74.6 95% 84% complex -
8*∆ F 61 M5 AML with myelodysplasia 82.1 77% 74% 46,XX,del12p,del20q -
9 F 39 M5 AML monoblastic 37.7 65% 94% 47,XX,t(3;11),+8 -
10∆ F 49 M4 AML with inv16 94.2 47% 57% 46,XX,inv16 FLT3m
11∆ M 58 M2 AML with t(8;21) 100.0 60% 58% 46,XY,t(8;21) -
12 M 23 M2 AML with t(8;21) 13.7 52% 59% 45,X,-Y, t(8;21) -
13 M 68 RAEB
-T AML with myelodysplasia 3.5 0% 20% 46,XY -
14∆ M 21 M1 AML without maturation 133.2 95% 88% 46,XY,add(17p) -
15*∆ M 49 sec. AML with myelodysplasia 89.7 85% n.t. 46,XY -
16*∆ M 68 M6a Acute erythroid leukemia 6.1 93% 93% n.t. -
17* M 44 M4 AML myelomonocytic 90.2 91% 92% complex -
18 F 41 M4 AML myelomonocytic 2.8 51% 72% 46,XX -
19 F 72 M4 Therapy-related AML 93.2 62% 74% 46,XX FLT3m, NPM1m
20 F 52 M1 AML with mutated NPM1 64.1 88% 80% 46,XX NPM1m
21*∆ F 73 M1 AML without maturation 75.6 73% 84% 46,XX,t(3;?) FLT3m
22* F 65 sec. AML with myelodysplasia 4.2 0% 19% 46,XX FLT3m
23* M 70 sec. AML with myelodysplasia 1.9 25% 15% complex -
24* M 26 M4 AML myelomonocytic 93.9 76% 76% 46,XY FLT3m
25* M 71 sec. AML with myelodysplasia 13.0 77% 46% 46,XY NPM1m, KIT D816V
26 F 45 M4 AML with myelodysplasia 66.8 53% 66% 46,XX FLT3m
27* M 72 M4 AML monocytic 20.3 37% 34% 46,XY,+11,-16 FLT3m
28 M 40 M1 AML with mutated NPM1 202.3 61% 65% 46,XY NPM1m, FLT3m
29 M 75 sec. AML with myelodysplasia 18.8 29% 21% 47,XY,+mar JAK2 V617F, FLT3m
30 F 50 M5 AML with mutated NPM1 50.9 4% 23% 46,XX NPM1m
31∆ F 65 M4 AML with myelodysplasia 62.2 79% 70% complex -
32*∆ F 54 M1 AML without maturation 23.3 81% n.t. n.t. -
33*∆ M 59 sec. AML with myelodysplasia 34.3 26% n.t. 47,XY,add(3),+8 -
34∆ F 84 M4 AML myelomonocytic 132.0 8% 29% 46,XX -
35∆ F 85 M1 AML with myelodysplasia 1.7 0% 33% 46,XX,del5q -
36∆ M 64 M1 AML with maturation 53.5 94% 84% 46,XY -
37*∆ M 53 M2 AML with myelodysplasia 2.8 16% 37% 45,XY,-7 -
 *These patients were analyzed at relapse or persistence of blasts. Abbreviations: WBC, white blood count; F, female; M, male; Yrs, years; FAB, French-
American-British cooperative study group; WHO, World Health Organization; PB, peripheral blood; BM, bone marrow; n.t., not tested; FLT3m, mutated 
FLT3; NPM1m, mutated NPM1; CEBPAm, mutated CEBPA. ∆These patients were purified for CD34+/CD38- and CD34+/CD38+ subfractions by cell 
sorting.Oncotarget 2012; 3: 1588-1599 1595 www.impactjournals.com/oncotarget
clinical implications. In addition, our data are the first 
to show that a drug combination consisting of a BET 
bromodomain inhibitor and ARA-C, can produce strong 
synergistic growth-inhibitory effects in AML cells.
Expression of BRD4 in AML stem- and progenitor 
cells was demonstrable by qPCR and by immunostaining. 
Both the CD34+/CD38- and the CD34+/CD38+ stem- 
and progenitor cells contained BRD4 mRNA as well as 
the BRD4 protein in all categories of AML, including 
refractory or relapsing disease. In addition, all AML 
cell lines examined were found to express BRD4. An 
interesting observation was that normal CD34+ stem 
cells also expressed BRD4, with similar expression 
levels compared to LSC. In addition, myeloid progenitor 
cells and even mature granulocytic cells were found to 
express BRD4 in the normal BM. These data suggest that 
targeting of BRD4 may result in a decreased production 
of normal BM cells. Indeed, we were able to show that 
JQ1 inhibits the growth of normal BM cells in vitro. 
However, the concentrations required to fully block 
growth of normal BM cells were higher as that required 
to block proliferation of AML blasts. This difference may 
well provide a “pharmacological window” sufficient to 
introduce JQ1 or similar BET bromodomain  inhibitors 
in clinical trials. In line with this assumption, JQ1 was not 
found to act as a myelosuppressive agent when applied in 
vivo in various mouse models [33].
BRD4 is a well known transcriptional regulator 
and chromatin modifier that plays a key role in cell cycle 
progression in normal and neoplastic cells [34-36]. More 
recent data suggest, that BRD4 exhibits atypical kinase 
activity and interacts with a number of nuclear and 
cytoplasmic interaction-partners such as SPA-1 [37,38]. 
In the present study, we were able to show that BRD4 is 
expressed in the cytoplasm and in nuclei of AML blasts 
and CD34+CD38- AML LSC. The prominent cytoplasmic 
location of BRD4 was somehow unexpected and suggests 
that BRD4 may fulfil as yet unknown biological functions 
in the cytoplasmic compartment of AML cells. An 
interesting observation was that BRD4 is also expressed 
in the cytoplasm and nuclei of normal bone marrow cells 
and highly enriched cord blood progenitor cells, although 
the expression levels were lower compared to AML cells. 
However, even in terminally differentiated non-dividing 
BM cells, BRD4 was found to be expressed in the 
cytoplasmic and nuclear compartment. These observations 
suggest  that  BRD4  may  fulfil  important  functions  in 
normal and neoplastic hematopoiesis, including immature 
myeloid stem- and progenitor cells and both the nuclear 
and cytoplamic compartment of these cells.
We have recently shown that the BRD4-blocking 
drug  JQ1  induces  growth  inhibition  and  apoptosis  in 
human and murine AML cells [33]. In the present study, 
we have extended these investigations and asked whether 
JQ1 would also block the growth and survival of leukemic 
cells in patients with relapsed or resistant AML. Indeed, 
our results show that JQ1 induces growth inhibition and 
apoptosis with reasonable IC50 values in primary AML 
cells in almost all patients examined, including patients 
with relapsed or resistant disease. This observation is of 
particular interest and may have clinical implications. 
In fact, these patients have a very poor prognosis, and 
novel drugs will be required to improve therapy. Whether 
indeed BRD4-targeting agents will be successful in the 
treatment of AML remains at present unknown. Based 
on our promising preclinical results, we recommend that 
BET bromodomain inhibitors should be evaluated for their 
efficacy in AML in forthcoming clinical trials.
As mentioned above, LSC are a major operational 
target of drug therapy [26-32,39]. In order to learn 
whether JQ1 would act anti-leukemic at the LSC level, 
we analyzed responses of CD34+CD38- cells and CD34+/
CD38+ cells to JQ1. In these experiments, JQ1 was found 
to induce apoptosis of CD34+CD38- and CD34+/CD38+ 
Figure 4: Synergistic growth-inhibitory effects of JQ1 
and ARA-C on growth of AML cells. HL60 cells (upper 
panel) and KG1 cells (lower panel) were incubated in control 
medium or in medium containing various concentrations of 
JQ1, various concentrations of cytosine arabinoside (ARA-C), 
or a combination of both drugs at various concentrations at a 
fixed drug-ratio (20:1 for HL60 cells and 10:1 for KG1). Drugs 
were applied at 37°C for 48 hours. After incubation, uptake of 
3H-thymidine was measured. Results are expressed as percent 
of medium control. Result of one typical experiment are shown. 
Almost the same results were obtained in 2 other independent 
experiments. Oncotarget 2012; 3: 1588-1599 1596 www.impactjournals.com/oncotarget
stem- and progenitor cells in all patients examined, 
including patients with relapsing or resistant AML. These 
data  suggest  that  JQ1  may  be  capable  of  eradicating 
LSC, an assumption that needs to be confirmed in further 
preclinical and clinical studies.
Many of the novel anti-leukemic drugs used to treat 
refractory AML are applied in combination with other anti-
AML agents [40-42]. Therefore, it was of considerable 
interest to learn whether JQ1 would cooperate or even 
synergize with established  chemotherapeutics when 
applied on AML cells. In the present study, we were able 
to show that JQ1 and ARA-C produce clear synergistic 
effects when used in combination to treat AML cells. This 
observation is of clinical importance and would be in favor 
of novel treatment concepts combining JQ1 or similar 
BRD4 inhibitors and ARA-C in patients with relapsing or 
refractory AML in clinical trials.
In conclusion, we have identified BRD4 as a novel 
drug target expressed in AML cells including AML LSC, 
and that JQ1 is an effective agent capable of blocking 
growth of AML cells and LSC through BRD4 inhibition. 
These observations may have clinical implications, as 
BRD4 blockers like JQ1 and similar agents may soon be 
applied in clinical trials to treat AML. Whether these drugs 
will improve therapy in relapsed or resistant AML remains 
to be determined.
PATIENTS AND METHODS
Patients and isolation of AML cells
A total number of 37 patients with AML (females, 
n=16; males, n=21) were examined. The median age was 
59 years (range: 21-85 years). Diagnoses were established 
according to the proposal of the French-American-
British (FAB) cooperative study group [43,44] and the 
classification of the World Health organization (WHO) 
[45]. Of the 37 patients, 23 had freshly diagnosed AML, 
and 14 suffered from refractory or relapsed AML. The 
patients´ characteristics are shown in Table 3. For control 
purpose we examined bone marrow (BM) cells obtained 
from one patient with Non-Hodgkin´s lymphoma without 
BM involvement, one with idiopathic cytopenia, and one 
with chronic myeloid leukemia (CML) in major molecular 
remission. Informed consent was obtained prior to BM 
puncture in each case. The study was approved by the 
Institutional Review Board (Ethics Committee) of the 
Medical University of Vienna. Mononuclear cells (MNC) 
were prepared using Ficoll and stored in liquid nitrogen 
until used or were used as freshly prepared MNC. After 
thawing, the viability of AML cells ranged from 75% to 
99% as assessed by trypan blue exclusion. 
Cell lines
AML cell lines used in this study were HL60, 
U937, KG1, MV4-11, and MOLM-13 (all from the 
German Collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany). Cell lines were maintained in 
RPMI 1640 medium supplemented with 10% fetal calf 
serum (FCS; PAA laboratories, Pasching, Austria) at 5% 
CO2 and 37°C. 
Immunocytochemistry (ICC) and immuno-
histochemistry (IHC)
To confirm expression of BRD4 in leukemic cells, 
ICC and IHC were performed according to published 
protocols [46-48]. ICC was performed on AML cell lines 
(U937, HL-60, KG-1, MV4-11, MOLM-13), primary 
AML MNC, and sorted CD34+/CD38- AML LSC. 
Cells were spun on cytospin slides and incubated with 
a polyclonal rabbit anti-human BRD4 antibody (Sigma-
Aldrich, St.Louis, MO; work dilution 1:100) for 20 hours. 
Cells were then washed and incubated with biotinylated 
goat-anti-rabbit IgG for 30 minutes. As chromogen, 
alkaline phosphatase complex (Biocare, Walnut Creek, 
CA) was used. Antibody-reactivity was made visible 
by  Neofuchsin  (Nichirei,  Tokyo,  Japan).  In  control 
experiments, the anti-BRD4 antibody was preincubated 
with control buffer or a BRD4-specific blocking peptide 
(Bethyl Laboratories, Montgomery, TX) for 1 hour before 
ICC or IHC were carried out. 
IHC was performed on sections prepared from 
paraffin-embedded, formalin-fixed BM biopsy specimens 
(AML, n=13; normal/reactive BM: n=6) using the indirect 
immunoperoxidase staining technique as reported [46-48]. 
Prior to staining, sections were pretreated by microwave 
oven. Endogenous peroxidase was blocked by methanol/
H2O2. Slides were incubated with anti-BRD4 antibody 
(Sigma-Aldrich, work dilution: 1:50; pH 7.5) at 4°C for 
20 hours. Then, slides were washed and incubated with 
biotinylated  anti-mouse IgG (Vector, Burlingame, CA) 
for 30 minutes,  washed, and then exposed to Vectastain 
ABC KIT for 30 minutes. 3-amino-9-ethylcarbazole 
(AEC, Sigma) was used as chromogen. All slides were 
counterstained in Mayer´s Hemalaun.
Evaluation of proliferation by measuring 
3H-thymidine uptake 
Primary cells (MNC) were cultured in 96-well 
microtiter plates (TPP, Trasadingen, Switzerland) (5-
10 x 104 cells/well) in RPMI 1640 medium (PAA 
laboratories) plus 10% FCS in the absence or presence of 
JQ1 (10-5,000 nM) at 37°C (5% CO2). After 48 hours, 
0.5 µCi 3H-thymidine was added (16 hours). Cells were Oncotarget 2012; 3: 1588-1599 1597 www.impactjournals.com/oncotarget
then harvested on filter membranes in a Filtermate 196 
harvester (Packard Bioscience, Meriden, CT). Filters 
were air-dried, and the bound radioactivity was measured 
in a ß-counter (Top-Count NXT, Packard Bioscience). All 
experiments were performed in triplicates. Proliferation 
was calculated as percent of medium control, and the 
inhibitory effects of JQ1 were expressed as IC50 values. 
In a separate set of experiments, AML cell lines (KG-1, 
HL60) were incubated in various concentrations of JQ1, 
various concentrations of ARA-C, or a combination of 
both drugs at fixed ratio of drug-concentrations.
Flow cytometric evaluation of apoptosis in AML 
cells
Primary AML cells (n=9) were incubated in RPMI 
1640 medium and 10% FCS in the absence or presence 
of various concentrations of JQ1 (10-5,000 nM) at 37°C 
(5% CO2) for 48 hours. Thereafter, cells were subjected 
to  flow  cytometry  experiments  following  published 
protocols [48-51]. Apoptosis was measured by combined 
Annexin-V/propidium-iodide staining and caspase-
staining. Before being stained with rabbit anti-human 
monoclonal antibody (mAb) C92-605 (Becton Dickinson 
Biosciences) directed against active caspase 3, cells were 
fixed in paraformaldehyde (2%) and permeabilized in 
methanol at -20°C (15 minutes). Then, cells were washed 
and analyzed on a FACSCalibur (Becton Dickinson 
Biosciences). Apoptosis was expressed as percentage of 
active caspase 3-positive cells. 
To study apoptosis in stem- and progenitor cells, 
CD45+/CD34+/CD38+ BM progenitor cells and CD45+/
CD34+/CD38− BM stem cells were examined for apoptosis 
by combined staining for surface antigens, 4´,6-diamidino-
2-phenylindole (DAPI; Invitrogen, Carlsbad, CA) and 
Annexin-V-FITC (eBioscience, San Diego, CA) as 
described [51]. Apoptosis was expressed as percent of 
Annexin-V+ cells after gating for DAPI-negative cells 
(early apoptotic cells). The mAb used to identify stem- 
and progenitor cells were phycoerythrin-labeled CD34 
mAb 581, the allophycocyanin-labeled CD38 mAb HIT2, 
and the peridinin chlorophyll protein-labeled CD45 mAb 
2D1 (all from BD Biosciences, San José, CA).
Purification of CD34+/CD38+ cells and CD34+/
CD38− cells by cell-sorting
In 15 patients with AML (patients #4, #8, #10, #11, 
#14, #15, #16, #21, #31, #32, #33, #34, #35, #36, #37 
in Table 3), CD34+/CD38− stem cells and CD34+/CD38+ 
progenitor cells were highly enriched by mAb and cell 
sorting essentially as described [50,51]. The purity of the 
sorted cells amounted to >98%. 
Reverse transcriptase PCR (RT-PCR) and 
quantitative PCR (qPCR)
PCR experiments were performed on RNA from 
AML cell lines, unfractionated AML cells, sorted CD34+/
CD38+ and CD34+/CD38− AML cells (n=9) and sorted 
cord blood CD34+/CD38+ and CD34+/CD34− cells pooled 
from 3 donors. RNA was isolated using RNeasy Mini-
Kit  (Qiagen,  Hilden,  Germany).  mRNA  levels  were 
quantified on a 7900HT Fast Real-Time PCR System 
from Applied Biosystems (Foster City, CA), using 
iTaq SYBR Green Supermix with ROX from Bio-Rad 
(Hercules, CA). ABL was employed as a reference gene. 
Primers used in this study were: hu BRD4-forward:5`-
GCCCGCAAGCTCCA GGATGT-3`;hu BRD4-reverse: 
5`-CCTCAGGCTCGTCCGGCATC-3`; hu ABL-forward: 
5`-TGTATGATTTTGTGGCCAGTGGAG-3`; and hu 
ABL-reverse: 5`-GC CTAAGACCCGGAGCTTTTCA-3`.
Statistical analysis
Differences in growth and apoptosis in drug-
exposed cells were determined by appropriate statistical 
analysis, including the paired student´s t test. Results were 
considered to be significantly different when the p value 
was <0.05.
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